Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1Phase 1 1

Status

Recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4UNKNOWN 1OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 3Head & Neck 2Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 57Stomach Neoplasms 45Carcinoma, Non-Small-Cell Lung 36Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Lung Neoplasms 11Esophageal Neoplasms 11Nasopharyngeal Carcinoma 10Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Liver Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Turcot syndrome 2

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × sintilimab × Clear all
NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Recruiting
33 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

Tongji Hospital

Phase 3 Not yet recruiting
400 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07455617 2026-04-06

Study of ABO2102 in KRAS-Mutated Solid Tumors

Suzhou Abogen Biosciences Co., Ltd.

Phase 1 Recruiting
101 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Sun Yat-sen University

Phase 2 Recruiting
36 enrolled
Gastrointestinal

Appendiceal Neoplasms, Neoplasm Metastasis

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Henan Cancer Hospital

Phase 2 Completed
42 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05136768 2021-11-29

LM-HNSCC

ChineseAMS

Phase 2 Unknown
50 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT04398927 2021-02-04

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Sun Yat-sen University

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡